{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:10Z","timestamp":1786979950431,"version":"build-2736575974"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004173","name":"Universidad Aut\u00f3noma Metropolitana","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004173","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universidad Autonoma Metropolitana"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug repurposing, also known as drug repositioning, is a currently tested approach by which new uses are being assigned for already tested drugs. In this case there are antibiotics that are used to combat bacterial infections. However, antibiotics are among the drugs that have been studied for possible antiviral activities. Therefore, the aim of this work is to carry out a review of the studies of antibiotics that could be repositioned for the treatment of viral infections. Among the main antibiotics that have demonstrated antiviral activity are macrolides and glycopeptides. In addition, several antibiotics from the group of tetracyclines, fluoroquinolones, cephalosporins and aminoglycosides have also been studied for their antiviral activity. These antibiotics have demonstrated antiviral activity against both RNA and DNA viruses, including the recent pandemic virus SARS-CoV-2. Some of these antibiotics were selected in addition to its antiviral activity for their immunomodulatory and anti-inflammatory properties. Of the antibiotics that present antiviral activity, in many cases the mechanisms of action are not exactly known. The use of these antibiotics to combat viral infections remains controversial and is not generally accepted, since clinical trials are required to prove its effectiveness. Therefore, there is currently no antibiotic approved as antiviral therapy. Hence is necessary to present the studies carried out on antibiotics that can be repositioned in the future as antiviral drugs.<\/jats:p>","DOI":"10.1007\/s00284-024-03948-7","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T04:05:41Z","timestamp":1729915541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Repositioning of Antibiotics in the Treatment of Viral Infections"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9906-0227","authenticated-orcid":false,"given":"Ana\u00edd","family":"Bustos-Hamdan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair Isidoro","family":"Bracho-Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5827-3576","authenticated-orcid":false,"given":"A\u00edda","family":"Hamdan-Partida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9763-754X","authenticated-orcid":false,"given":"Jaime","family":"Bustos-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"issue":"657","key":"3948_CR1","doi-asserted-by":"publisher","first-page":"eabo7793","DOI":"10.1126\/scitranslmed.abo7793","volume":"14","author":"MA Cook","year":"2022","unstructured":"Cook MA, Wright GD (2022) The past, present, and future of antibiotics. Sci Transl Med 14(657):eabo7793. https:\/\/doi.org\/10.1126\/scitranslmed.abo7793","journal-title":"Sci Transl Med"},{"key":"3948_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2344\/0003-3006-60.3.111","volume":"60","author":"DE Becker","year":"2013","unstructured":"Becker DE (2013) Antimicrobial drugs. Anesth Prog 60:111\u2013122. https:\/\/doi.org\/10.2344\/0003-3006-60.3.111. (quiz 123)","journal-title":"Anesth Prog"},{"key":"3948_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1126\/science.aaa3778","volume":"348","author":"E Bekerman","year":"2015","unstructured":"Bekerman E, Einav S (2015) Infectious disease. Combating emerging viral threats. Science 348:282\u2013283. https:\/\/doi.org\/10.1126\/science.aaa3778","journal-title":"Science"},{"key":"3948_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2015.11.003","volume":"125","author":"Y Wang","year":"2016","unstructured":"Wang Y, Cui R, Li G, Gao Q, Yuan S, Altmeyer R, Zou G (2016) Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antivir Res 125:1\u20137. https:\/\/doi.org\/10.1016\/j.antiviral.2015.11.003","journal-title":"Antivir Res"},{"key":"3948_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ijantimicag.2016.07.004","volume":"48","author":"P Colson","year":"2016","unstructured":"Colson P, Raoult D (2016) Fighting viruses with antibiotics: an overlooked path. Int J Antimicrob Agents 48:349\u2013352. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.07.004","journal-title":"Int J Antimicrob Agents"},{"key":"3948_CR6","volume-title":"Principles of virology","author":"SJ Flint","year":"2020","unstructured":"Flint SJ, Racaniello VR, Rall GF, Hatziioannou T, Skalka AM (2020) Principles of virology, 5th edn. ASM Press, Washington, DC","edition":"5"},{"key":"3948_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/B978-0-12-800837-9.00002-2","volume-title":"Virus as populations","author":"E Domingo","year":"2016","unstructured":"Domingo E (2016) Molecular basis of genetic variation of viruses: error-prone replication. In: Virus as populations. Academic Press, Cambridge, pp 35\u201371. https:\/\/doi.org\/10.1016\/B978-0-12-800837-9.00002-2"},{"key":"3948_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1128\/br.35.3.235-241.1971","volume":"35","author":"D Baltimore","year":"1971","unstructured":"Baltimore D (1971) Expression of animal virus genomes. Bacteriol Rev 35:235\u2013241. https:\/\/doi.org\/10.1128\/br.35.3.235-241.1971","journal-title":"Bacteriol Rev"},{"key":"3948_CR9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/bcp.13851","volume":"85","author":"D Cavalla","year":"2019","unstructured":"Cavalla D (2019) Using human experience to identify drug repurposing opportunities: theory and practice. Br J Clin Pharmacol 85:680\u2013689. https:\/\/doi.org\/10.1111\/bcp.13851","journal-title":"Br J Clin Pharmacol"},{"key":"3948_CR10","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 380:2095\u20132128. https:\/\/doi.org\/10.1016\/S0140-6736(12)61728-0","journal-title":"The Lancet"},{"key":"3948_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41579-022-00820-y","volume":"21","author":"EM Darby","year":"2023","unstructured":"Darby EM, Trampari E, Siasat P, Gaya MS, Alav I, Webber MA, Blair JMA (2023) Molecular mechanisms of antibiotic resistance revisited. Nat Rev Microbiol 21:280\u2013295. https:\/\/doi.org\/10.1038\/s41579-022-00820-y","journal-title":"Nat Rev Microbiol"},{"key":"3948_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","volume":"21","author":"W Sun","year":"2016","unstructured":"Sun W, Sanderson PE, Zheng W (2016) Drug combination therapy increases successful drug repositioning. Drug Discov Today 21:1189\u20131195. https:\/\/doi.org\/10.1016\/j.drudis.2016.05.015","journal-title":"Drug Discov Today"},{"key":"3948_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/106002809202600112","volume":"26","author":"N Bahal","year":"1992","unstructured":"Bahal N, Nahata MC (1992) The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 26:46\u201355. https:\/\/doi.org\/10.1177\/106002809202600112","journal-title":"Ann Pharmacother"},{"key":"3948_CR14","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1128\/AAC.31.12.1948","volume":"3","author":"AE Girard","year":"1987","unstructured":"Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA (1987) Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 3:1948\u20131954. https:\/\/doi.org\/10.1128\/AAC.31.12.1948","journal-title":"Antimicrob Agents Chemother"},{"key":"3948_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rmv.2163","volume":"31","author":"ME Oliver","year":"2021","unstructured":"Oliver ME, Hinks TSC (2021) Azithromycin in viral infections. Rev Med Virol 31:1\u201313. https:\/\/doi.org\/10.1002\/rmv.2163","journal-title":"Rev Med Virol"},{"key":"3948_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1183\/09031936.00095809","volume":"36","author":"V Gielen","year":"2010","unstructured":"Gielen V, Johnston SL, Edwards MR (2010) Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 36:646\u2013654. https:\/\/doi.org\/10.1183\/09031936.00095809","journal-title":"Eur Respir J"},{"key":"3948_CR17","doi-asserted-by":"publisher","first-page":"112682","DOI":"10.1016\/j.biopha.2022.112682","volume":"147","author":"S Khoshnood","year":"2022","unstructured":"Khoshnood S, Shirani M, Dalir A, Moradi M, Haddadi MH, Sadeghifard N, Birjandi FS, Yashmi I, Heidary M (2022) Antiviral effects of azithromycin: a narrative review. Biomed Pharmacother 147:112682. https:\/\/doi.org\/10.1016\/j.biopha.2022.112682","journal-title":"Biomed Pharmacother"},{"key":"3948_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/2772432817666220106162013","volume":"18","author":"B Abadi","year":"2023","unstructured":"Abadi B, Ilaghi M, Shahsavani Y, Faramarzpour M, Oghazian MB, Rahimi HR (2023) Antibiotics with antiviral and anti-inflammatory potential against Covid-19: a review. Curr Rev Clin Exp Pharmacol 18:51\u201363. https:\/\/doi.org\/10.2174\/2772432817666220106162013","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"3948_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12941-021-00444-9","volume":"20","author":"A Yacouba","year":"2021","unstructured":"Yacouba A, Olowo-Okere A, Yunusa I (2021) Repurposing of antibiotics for clinical management of COVID-19: a narrative review. Ann Clin Microbiol Antimicrob 20:37. https:\/\/doi.org\/10.1186\/s12941-021-00444-9","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"3948_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jcf.2012.04.006","volume":"11","author":"S Asner","year":"2012","unstructured":"Asner S, Waters V, Solomon M, Yau Y, Richardson SE, Grasemann H, Gharabaghi F, Tran D (2012) Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros 11:433\u2013439. https:\/\/doi.org\/10.1016\/j.jcf.2012.04.006","journal-title":"J Cyst Fibros"},{"key":"3948_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.antiviral.2009.05.003","volume":"83","author":"M Asada","year":"2009","unstructured":"Asada M, Yoshida M, Suzuki T, Hatachi Y, Sasaki T, Yasuda H, Nakayama K, Nishimura H, Nagatomi R, Kubo H, Yamaya M (2009) Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. Antivir Res 83:191\u2013200. https:\/\/doi.org\/10.1016\/j.antiviral.2009.05.003","journal-title":"Antivir Res"},{"key":"3948_CR22","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.jaci.2014.10.001","volume":"135","author":"A Beigelman","year":"2015","unstructured":"Beigelman A, Isaacson-Schmid M, Sajol G (2015) Randomized trial to evaluate azithromycin\u2019s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 135:1171\u20131178. https:\/\/doi.org\/10.1016\/j.jaci.2014.10.001","journal-title":"J Allergy Clin Immunol"},{"key":"3948_CR23","doi-asserted-by":"publisher","first-page":"e012060","DOI":"10.1136\/bmjopen-2016-012060","volume":"6","author":"RA Mosquera","year":"2016","unstructured":"Mosquera RA, Gomez-Rubio AM, Harris T, Yadav A, McBeth K et al (2016) Anti-inflammatory effect of prophylactic macrolides on children with chronic lung disease: a protocol for a double-blinded randomised controlled trial. BMJ Open 6:e012060. https:\/\/doi.org\/10.1136\/bmjopen-2016-012060","journal-title":"BMJ Open"},{"key":"3948_CR24","doi-asserted-by":"publisher","first-page":"e12953","DOI":"10.1111\/cpr.12953","volume":"54","author":"X Du","year":"2021","unstructured":"Du X, Zuo X, Meng F, Han C, Ouyang W, Han Y, Gu Y, Zhao X, Xu F, Qin FX (2021) Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. Cell Prolif 54:e12953. https:\/\/doi.org\/10.1111\/cpr.12953","journal-title":"Cell Prolif"},{"issue":"5","key":"3948_CR25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.anai.2024.01.001","volume":"132","author":"A Beigelman","year":"2024","unstructured":"Beigelman A, Goss CW, Wang J, Srinivasan M, Boomer J et al (2024) Azithromycin therapy in infants hospitalized for respiratory syncytial virus bronchiolitis: airway matrix metalloproteinase-9 levels and subsequent recurrent wheeze. Ann Allergy Asthma Immunol 132(5):623\u2013629. https:\/\/doi.org\/10.1016\/j.anai.2024.01.001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3948_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.antiviral.2017.05.008","volume":"144","author":"N Lee","year":"2018","unstructured":"Lee N, Wong CK, Chan MCW, Yeung ESL, Tam WWS et al (2018) Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial. Antiviral Res 144:48\u201356. https:\/\/doi.org\/10.1016\/j.antiviral.2017.05.008","journal-title":"Antiviral Res"},{"key":"3948_CR27","doi-asserted-by":"publisher","first-page":"14408","DOI":"10.1073\/pnas.1618029113","volume":"113","author":"H Retallack","year":"2016","unstructured":"Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT et al (2016) Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci USA 113:14408\u201314413. https:\/\/doi.org\/10.1073\/pnas.1618029113","journal-title":"Proc Natl Acad Sci USA"},{"issue":"789\u2013793","key":"3948_CR28","doi-asserted-by":"publisher","first-page":"e00394","DOI":"10.1128\/AAC.00394-19","volume":"63","author":"C Li","year":"2019","unstructured":"Li C, Zu S, Deng YQ, Li D, Parvatiyar K et al (2019) Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses. J Antimicrob Agents Chemother 63(789\u2013793):e00394-e419. https:\/\/doi.org\/10.1128\/AAC.00394-19","journal-title":"J Antimicrob Agents Chemother"},{"key":"3948_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4172\/1948-5964.1000173","volume":"10","author":"E Bosseboeuf","year":"2018","unstructured":"Bosseboeuf E, Aubry M, Nhan T, de Pina JJ, Rolain JM, Raoult D, Musso D (2018) Azithromycin inhibits the replication of Zika virus. J Antivir Antiretrovir 10:6\u201311. https:\/\/doi.org\/10.4172\/1948-5964.1000173","journal-title":"J Antivir Antiretrovir"},{"key":"3948_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ijantimicag.2018.12.009","volume":"53","author":"L Zeng","year":"2019","unstructured":"Zeng L, Jiang X, Guo X (2019) Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo. Int J Antimicrob Agents 53:362\u2013369. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.12.009","journal-title":"Int J Antimicrob Agents"},{"key":"3948_CR31","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56:105949. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949","journal-title":"Int J Antimicrob Agents"},{"key":"3948_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5582\/bst.2020.03058","volume":"14","author":"M Ohe","year":"2020","unstructured":"Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, Goudarzi H (2020) Macrolide treatment for COVID-19: will this be the way forward? BioSci Trends 14:159\u2013160. https:\/\/doi.org\/10.5582\/bst.2020.03058","journal-title":"BioSci Trends"},{"key":"3948_CR33","unstructured":"World Health Organization (2024) International registry clinical trials platform. https:\/\/www.who.int\/clinical-trials-registry-platform\/the-ictrp-search-portal. Accessed 13 Sept 2024"},{"key":"3948_CR34","unstructured":"National Institutes of Health (2024). https:\/\/www.clinicaltrials.gov\/. Accessed 13 Sept 2024"},{"key":"3948_CR35","doi-asserted-by":"publisher","first-page":"101188","DOI":"10.1016\/j.nmni.2023.101188","volume":"55","author":"P Brouqui","year":"2023","unstructured":"Brouqui P, Million M, Parola P, Mccullough PA, Raoult D (2023) Outcomes after early treatment with hydroxychloroquine and azithromycin: an analysis of a database of 30,423 COVID-19 patients. New Microbes New Infect 55:101188. https:\/\/doi.org\/10.1016\/j.nmni.2023.101188","journal-title":"New Microbes New Infect"},{"key":"3948_CR36","doi-asserted-by":"publisher","first-page":"e2258","DOI":"10.1002\/rmv.2258","volume":"32","author":"AM Kamel","year":"2022","unstructured":"Kamel AM, Monem MSA, Sharaf NA, Magdy N, Farid SF (2022) Efficacy and safety of azithromycin in Covid-19 patients: a systematic review and meta-analysis of randomized clinical trials. Rev Med Virol 32:e2258. https:\/\/doi.org\/10.1002\/rmv.2258","journal-title":"Rev Med Virol"},{"key":"3948_CR37","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group (2021) Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 397:605\u2013612. https:\/\/doi.org\/10.1016\/S0140-6736(21)00149-5","journal-title":"The Lancet"},{"key":"3948_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"H Pan","year":"2021","unstructured":"Pan H, Peto R, Henao-Restrepo AM et al (2021) Repurposed antiviral drugs for Covid-19\u2014interim WHO Solidarity Trial Results. N Engl J Med 384:497\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa2023184","journal-title":"N Engl J Med"},{"key":"3948_CR39","doi-asserted-by":"publisher","first-page":"106053","DOI":"10.1016\/j.ijantimicag.2020.106053","volume":"56","author":"A Pani","year":"2020","unstructured":"Pani A, Lauriola M, Romandini A, Scaglione F (2020) Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrob Agents 56:106053. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106053","journal-title":"Int J Antimicrob Agents"},{"key":"3948_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1183\/09031936.06.00008005","volume":"27","author":"YJ Jang","year":"2006","unstructured":"Jang YJ, Kwon HJ, Lee BJ (2006) Effect of clarithromycin on rhinovirus-16 infection in A549 cells. Eur Respir J 27:12\u201319. https:\/\/doi.org\/10.1183\/09031936.06.00008005","journal-title":"Eur Respir J"},{"key":"3948_CR41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s004050050222","volume":"257","author":"K Fujita","year":"2000","unstructured":"Fujita K, Shimizu T, Majima Y, Sakakura Y (2000) Effects of macrolides on interleukin-8 secretion from human nasal epithelial cells. Eur Arch Otorhinolaryngol 257:199\u2013204. https:\/\/doi.org\/10.1007\/s004050050222","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"3948_CR42","first-page":"97","volume":"37","author":"M Van Kempen","year":"1999","unstructured":"Van Kempen M, Bachert C, Van Cauwenberge P (1999) An update on the pathophysiology of rhinovirus upper respiratory tract infections. Rhinology 37:97\u2013103","journal-title":"Rhinology"},{"key":"3948_CR43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.antiviral.2019.104591","volume":"171","author":"M Arikata","year":"2019","unstructured":"Arikata M, Itoh Y, Shichinohe S, Nakayama M, Ishigaki H, Kinoshita T, Le MQ, Kawaoka Y, Ogasawara K, Shimizu T (2019) Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys. Antivir Res 171:104\u2013109. https:\/\/doi.org\/10.1016\/j.antiviral.2019.104591","journal-title":"Antivir Res"},{"issue":"9","key":"3948_CR44","doi-asserted-by":"publisher","first-page":"e053325","DOI":"10.1136\/bmjopen-2021-053325","volume":"11","author":"K Yamamoto","year":"2021","unstructured":"Yamamoto K, Hosogaya N, Sakamoto N, Yoshida H, Ishii H, Yatera K, Izumikawa K, Yanagihara K, Mukae H (2021) Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID-19 study). BMJ Open 11(9):e053325. https:\/\/doi.org\/10.1136\/bmjopen-2021-053325","journal-title":"BMJ Open"},{"key":"3948_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12941-020-00358-y","volume":"19","author":"J Mill\u00e1n-O\u00f1ate","year":"2020","unstructured":"Mill\u00e1n-O\u00f1ate J, Millan W, Mendoza LA, S\u00e1nchez CG, Fernandez-Suarez H, Bonilla-Aldana DK, Rodr\u00edguez-Morales AJ (2020) Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Ann Clin Microbiol Antimicrob 19:16. https:\/\/doi.org\/10.1186\/s12941-020-00358-y","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"3948_CR46","doi-asserted-by":"publisher","first-page":"16361","DOI":"10.1038\/s41598-021-95900-z","volume":"11","author":"A Rashad","year":"2021","unstructured":"Rashad A, Nafady A, Hassan MH, Mansour H, Taya U et al (2021) Therapeutic efficacy of macrolides in management of patients with mild COVID-19. Sci Rep 11:16361. https:\/\/doi.org\/10.1038\/s41598-021-95900-z","journal-title":"Sci Rep"},{"key":"3948_CR47","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cimid.2017.11.002","volume":"56","author":"E Takahashi","year":"2018","unstructured":"Takahashi E, Indalao IL, Sawabuchi T, Mizuno K, Sakai S, Kimoto T, Kim H, Kido H (2018) Clarithromycin suppresses induction of monocyte chemoattractant protein-1 and matrix metalloproteinase-9 and improves pathological changes in the lungs and heart of mice infected with influenza A virus. Comp Immunol Microbiol Infect Dis 56:6\u201313. https:\/\/doi.org\/10.1016\/j.cimid.2017.11.002","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"3948_CR48","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/v11111064","volume":"11","author":"X Wang","year":"2019","unstructured":"Wang X, Xia S, Zou P, Lu L (2019) Erythromycin estolate inhibits Zika virus infection by blocking viral entry as a viral inactivator. Viruses 11:1064. https:\/\/doi.org\/10.3390\/v11111064","journal-title":"Viruses"},{"key":"3948_CR49","doi-asserted-by":"publisher","first-page":"905248","DOI":"10.3389\/fcimb.2022.905248","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang X, Chen Y, Shi H, Zou P (2022) Erythromycin estolate is a potent inhibitor against HCoV-OC43 by directly inactivating the virus particle. Front Cell Infect Microbiol 12:905248. https:\/\/doi.org\/10.3389\/fcimb.2022.905248","journal-title":"Front Cell Infect Microbiol"},{"key":"3948_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1371\/journal.pone.0221560","volume":"23","author":"D Desmonts de Lamache","year":"2019","unstructured":"Desmonts de Lamache D, Moges R, Siddiq A, Allain T, Feener TD, Muench GP, McKenna N, Yates RM, Buret AG (2019) Immuno-modulating properties of tulathromycin in porcine monocyte-derived macrophages infected with porcine reproductive and respiratory syndrome virus. PLoS ONE 23:14. https:\/\/doi.org\/10.1371\/journal.pone.0221560","journal-title":"PLoS ONE"},{"key":"3948_CR51","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jvp.12742","volume":"42","author":"M Pomorska-M\u00f3l","year":"2019","unstructured":"Pomorska-M\u00f3l M, Kwit K, Czy\u017cewska-Dors E, Pejsak Z (2019) Tulathromycin enhances humoral but not cellular immune response in pigs vaccinated against swine influenza. J Vet Pharmacol Ther 42:318\u2013323. https:\/\/doi.org\/10.1111\/jvp.12742","journal-title":"J Vet Pharmacol Ther"},{"key":"3948_CR52","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41429-020-0336-z","volume":"73","author":"F Heidary","year":"2020","unstructured":"Heidary F, Gharebaghi R (2020) Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot 73:593\u2013602. https:\/\/doi.org\/10.1038\/s41429-020-0336-z","journal-title":"J Antibiot"},{"key":"3948_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41429-021-00491-6","volume":"75","author":"AK Zaidi","year":"2022","unstructured":"Zaidi AK, Dehgani-Mobaraki P (2022) The mechanisms of action of ivermectin against SARS-CoV-2\u2014an extensive review. J Antibiot 75:60\u201371. https:\/\/doi.org\/10.1038\/s41429-021-00491-6","journal-title":"J Antibiot"},{"issue":"4","key":"3948_CR54","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1097\/MJT.0000000000001402","volume":"28","author":"A Bryant","year":"2021","unstructured":"Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC (2021) Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther 28(4):e434\u2013e460. https:\/\/doi.org\/10.1097\/MJT.0000000000001402","journal-title":"Am J Ther"},{"key":"3948_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015017.pub2","author":"M Popp","year":"2021","unstructured":"Popp M, Stegemann M, Metzendorf M-I, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S (2021) Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD015017.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"3948_CR56","doi-asserted-by":"publisher","first-page":"106130","DOI":"10.1016\/j.jinf.2024.106130","volume":"88","author":"G Hayward","year":"2015","unstructured":"Hayward G, Yu LM, Little P, Gbinigie O, Shanyinde M et al (2015) Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes. J Infect 88:106130. https:\/\/doi.org\/10.1016\/j.jinf.2024.106130","journal-title":"J Infect"},{"key":"3948_CR57","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1021\/cr030103a","volume":"105","author":"D Kahne","year":"2005","unstructured":"Kahne D, Leimkuhler C, Lu W, Walsh C (2005) Glycopeptide and lipoglycopeptide antibiotics. Chem Rev 105:425\u2013448. https:\/\/doi.org\/10.1021\/cr030103a","journal-title":"Chem Rev"},{"key":"3948_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acsinfecdis.1c00367","volume":"8","author":"Y Acharya","year":"2022","unstructured":"Acharya Y, Bhattacharyya S, Dhanda G, Haldar J (2022) Emerging roles of glycopeptide antibiotics: moving beyond gram-positive bacteria. ACS Infect Dis 8:1\u201328. https:\/\/doi.org\/10.1021\/acsinfecdis.1c00367","journal-title":"ACS Infect Dis"},{"key":"3948_CR59","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1021\/jm0300882","volume":"46","author":"J Balzarini","year":"2003","unstructured":"Balzarini J, Pannecouque C, De Clercq E, Pavlov AY, Printsevskaya SS, Miroshnikova OV, Reznikova MI, Preobrazhenskaya MN (2003) Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics. J Med Chem 46:2755\u20132764. https:\/\/doi.org\/10.1021\/jm0300882","journal-title":"J Med Chem"},{"key":"3948_CR60","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.antiviral.2006.04.008","volume":"71","author":"MN Preobrazhenskaya","year":"2006","unstructured":"Preobrazhenskaya MN, Olsufyeva EN (2006) Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry. Antivir Res 71:227\u2013236. https:\/\/doi.org\/10.1016\/j.antiviral.2006.04.008","journal-title":"Antivir Res"},{"key":"3948_CR61","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ejmech.2018.08.058","volume":"1","author":"Z Sz\u0171cs","year":"2018","unstructured":"Sz\u0171cs Z, Kelemen V, Le Thai S, Cs\u00e1v\u00e1s M, R\u0151th E, Batta G, Stevaert A, Vanderlinden E, Naesens L, Herczegh P, Borb\u00e1s A (2018) Structure activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents. Eur J Med Chem 1:1017\u20131030. https:\/\/doi.org\/10.1016\/j.ejmech.2018.08.058","journal-title":"Eur J Med Chem"},{"key":"3948_CR62","doi-asserted-by":"publisher","first-page":"e37244","DOI":"10.1371\/journal.pone.0037244","volume":"7","author":"T De Burghgraeve","year":"2012","unstructured":"De Burghgraeve T, Kaptein SJ, Ayala-Nunez NV, Mondotte JA, Pastorino B, Printsevskaya SS, de Lamballerie X, Jacobs M, Preobrazhenskaya M, Gamarnik AV, Smit JM, Neyts J (2012) An analogue of the antibiotic teicoplanin prevents flavivirus entry in vitro. PLoS ONE 7:e37244. https:\/\/doi.org\/10.1371\/journal.pone.0037244","journal-title":"PLoS ONE"},{"key":"3948_CR63","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/jac\/dkr104","volume":"66","author":"S Obeid","year":"2011","unstructured":"Obeid S, Printsevskaya SS, Olsufyeva EN, Dallmeier K, Durantel D, Zoulim F, Preobrazhenskaya MN, Neyts J, Paeshuyse J (2011) Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. J Antimicrob Chem 66:1287\u20131294. https:\/\/doi.org\/10.1093\/jac\/dkr104","journal-title":"J Antimicrob Chem"},{"key":"3948_CR64","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1093\/jac\/dks217","volume":"67","author":"A Maieron","year":"2012","unstructured":"Maieron A, Kerschner H (2012) Teicoplanin therapy leading to a significant decrease in viral load in a patient with chronic hepatitis C. J Antimicrob Chemother 67:2537\u20132538. https:\/\/doi.org\/10.1093\/jac\/dks217","journal-title":"J Antimicrob Chemother"},{"key":"3948_CR65","doi-asserted-by":"publisher","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","volume":"291","author":"N Zhou","year":"2016","unstructured":"Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, Huang F, Peng T, Zhang J, Liu C, Tao L, Zhang H (2016) Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome\/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 291:9218\u20139232. https:\/\/doi.org\/10.1074\/jbc.M116.716100","journal-title":"J Biol Chem"},{"key":"3948_CR66","doi-asserted-by":"publisher","first-page":"884034","DOI":"10.3389\/fmicb.2022.884034","volume":"12","author":"F Yu","year":"2022","unstructured":"Yu F, Pan T, Huang F, Ying R, Liu J, Fan H, Zhang J, Liu W, Lin Y, Yuan Y et al (2022) Glycopeptide antibiotic teicoplanin inhibits cell entry of SARS-CoV-2 by suppressing the proteolytic activity of cathepsin L. Front Microbiol 12:884034. https:\/\/doi.org\/10.3389\/fmicb.2022.884034","journal-title":"Front Microbiol"},{"key":"3948_CR67","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/s41598-022-20182-y","volume":"12","author":"I Bereczki","year":"2022","unstructured":"Bereczki I, Vimberg V, L\u0151rincz E, Papp H, Nagy L et al (2022) Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria. Sci Rep 12:16001. https:\/\/doi.org\/10.1038\/s41598-022-20182-y","journal-title":"Sci Rep"},{"key":"3948_CR68","doi-asserted-by":"publisher","first-page":"105112","DOI":"10.1016\/j.ijantimicag.2020.105944","volume":"55","author":"SA Baron","year":"2020","unstructured":"Baron SA, Devaux C, Colson P, Raoult D, Rolain JM (2020) Teicoplanin: analternative drug for the treatment of COVID-19? Int J Antimicrob Agents 55:105112. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105944","journal-title":"Int J Antimicrob Agents"},{"key":"3948_CR69","doi-asserted-by":"publisher","first-page":"114213","DOI":"10.1016\/j.biopha.2023.114213","volume":"158","author":"L Ma","year":"2023","unstructured":"Ma L, Li Y, Shi T, Zhu Z, Zhao J, Xie Y, Wen J, Guo S, Wang J, Ding J, Liang C, Shan G, Li Q, Ge M, Cen S (2023) Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors. Biomed Pharmacother 158:114213. https:\/\/doi.org\/10.1016\/j.biopha.2023.114213","journal-title":"Biomed Pharmacother"},{"key":"3948_CR70","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ijantimicag.2020.106029","volume":"56","author":"G Ceccarelli","year":"2020","unstructured":"Ceccarelli G, Alessandri F, d\u2019Ettorre G, Borrazzo C, Spagnolello O, Oliva A, Ruberto F, Mastroianni CM, Pugliese F, Venditti M, Intensive Care COVID-19 Study Group of Sapienza University (2020) Is teicoplanin a complementary treatment option for COVID-19? The question remains. Int J Antimicrob Agents 56:106\u2013112. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106029","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"3948_CR71","doi-asserted-by":"publisher","first-page":"e14752","DOI":"10.1111\/ijcp.14752","volume":"75","author":"Z Yasar","year":"2021","unstructured":"Yasar Z, Yemisen M, Yasar H, Erta\u015f A, Meric K, Sahin S (2021) Can treatment with teicoplanin improve the prognosis of COVID-19 patients? Int J Clin Pract 75(11):e14752. https:\/\/doi.org\/10.1111\/ijcp.14752","journal-title":"Int J Clin Pract"},{"key":"3948_CR72","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1021\/jm0500774","volume":"48","author":"SS Printsevskaya","year":"2018","unstructured":"Printsevskaya SS, Solovieva SE, Olsufyeva EN, Mirchink EP, Isakova EB, De Clercq E, Balzarini J, Preobrazhenskaya MN (2018) Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin. J Med Chem 48:3885\u20133890. https:\/\/doi.org\/10.1021\/jm0500774","journal-title":"J Med Chem"},{"key":"3948_CR73","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/ph13070139","volume":"13","author":"Z Sz\u0171cs","year":"2020","unstructured":"Sz\u0171cs Z, Naesens L, Stevaert A, Ostorh\u00e1zi E, Batta G, Herczegh P, Borb\u00e1s A (2020) Reprogramming of the antibacterial drug vancomycin results in potent antiviral agents devoid of antibacterial activity. Pharmaceuticals (Basel) 13:139. https:\/\/doi.org\/10.3390\/ph13070139","journal-title":"Pharmaceuticals (Basel)"},{"key":"3948_CR74","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1134\/S0006297918100073","volume":"83","author":"G Cozza","year":"2018","unstructured":"Cozza G, Fortuna M, Meggio F, Sarno S, Kubbutat MHG et al (2018) Hydrophobic derivatives of glycopeptide antibiotics as inhibitors of protein kinases. Biochemistry (Mosc) 83:1222\u20131230. https:\/\/doi.org\/10.1134\/S0006297918100073","journal-title":"Biochemistry (Mosc)"},{"key":"3948_CR75","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1016\/j.bmcl.2010.03.080","volume":"20","author":"G Pinter","year":"2010","unstructured":"Pinter G, Bereczki I, Batta G, Otvos R, Sztaricskai F et al (2010) Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity. Bioorg Med Chem Lett 20:2713\u20132717. https:\/\/doi.org\/10.1016\/j.bmcl.2010.03.080","journal-title":"Bioorg Med Chem Lett"},{"key":"3948_CR76","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ejmech.2012.10.030","volume":"58","author":"A Sipos","year":"2012","unstructured":"Sipos A, Mate G, Roth E, Borbas A, Batta G (2012) Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities. Eur J Med Chem 58:361\u2013367. https:\/\/doi.org\/10.1016\/j.ejmech.2012.10.030","journal-title":"Eur J Med Chem"},{"key":"3948_CR77","doi-asserted-by":"publisher","first-page":"7092","DOI":"10.1016\/j.bmcl.2012.09.079","volume":"22","author":"A Sipos","year":"2012","unstructured":"Sipos A, T\u00f6r\u00f6k Z, R\u0151th E, Kiss-Szikszai A, Batta G, Bereczki I, Fejes Z, Borb\u00e1s A, Ostorh\u00e1zi E, Rozgonyi F, Naesens L, Herczegh P (2012) Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities. Bioorg Med Chem Lett 22:7092\u20137096. https:\/\/doi.org\/10.1016\/j.bmcl.2012.09.079","journal-title":"Bioorg Med Chem Lett"},{"key":"3948_CR78","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","volume":"65","author":"I Chopra","year":"2001","unstructured":"Chopra I, Roberts M (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232\u2013260. https:\/\/doi.org\/10.1128\/MMBR.65.2.232-260.2001","journal-title":"Microbiol Mol Biol Rev"},{"key":"3948_CR79","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1358\/mf.1998.20.8.487489","volume":"20","author":"FG Sturtz","year":"1998","unstructured":"Sturtz FG (1998) Antimurine retroviral effect of doxycycline. Methods Find Exp Clin Pharmacol 20:643\u2013647. https:\/\/doi.org\/10.1358\/mf.1998.20.8.487489","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"3948_CR80","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00705-013-1880-7","volume":"159","author":"HA Rothan","year":"2014","unstructured":"Rothan HA, Mohamed Z, Paydar M, Rahman NA, Yusof R (2014) Inhibitory effect of doxycycline against dengue virus replication in vitro. Arch Virol 159:711\u2013718. https:\/\/doi.org\/10.1007\/s00705-013-1880-7","journal-title":"Arch Virol"},{"key":"3948_CR81","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1574891x10666150410153839","volume":"10","author":"TM Fredeking","year":"2015","unstructured":"Fredeking TM, Zavala-Castro JE, Gonz\u00e1lez-Mart\u00ednez P, Moguel-Rodr\u00edguez W, Sanchez EC, Foster MJ, Diaz-Quijano FA (2015) Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. Recent Pat Antiinfect Drug Discov 10:51\u201358. https:\/\/doi.org\/10.2174\/1574891x10666150410153839","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"3948_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules26144321","volume":"26","author":"TC Teoh","year":"2021","unstructured":"Teoh TC, Al-Harbi SJ, Abdulrahman AY, Rothan HA (2021) Doxycycline interferes with zika virus serine protease and inhibits virus replication in human skin fibroblasts. Molecules 26:1\u20138. https:\/\/doi.org\/10.3390\/molecules26144321","journal-title":"Molecules"},{"key":"3948_CR83","doi-asserted-by":"publisher","first-page":"fnv195","DOI":"10.1093\/femsle\/fnv195","volume":"362","author":"ZC Wu","year":"2015","unstructured":"Wu ZC, Wang X, Wei JC, Li BB, Shao DH, Li YM, Liu K, Shi YY, Zhou B, Qiu YF, Ma ZY (2015) Antiviral activity of doxycycline against vesicular stomatitis virus in vitro. FEMS Microbiol Lett 362:fnv195. https:\/\/doi.org\/10.1093\/femsle\/fnv195","journal-title":"FEMS Microbiol Lett"},{"key":"3948_CR84","doi-asserted-by":"publisher","first-page":"11555","DOI":"10.1128\/jvi.77.21.11555-11562.2003","volume":"77","author":"MJ Bick","year":"2003","unstructured":"Bick MJ, Carroll JW, Gao G, Goff SP, Rice CM, MacDonald MR (2003) Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J Virol 77:11555\u201311562. https:\/\/doi.org\/10.1128\/jvi.77.21.11555-11562.2003","journal-title":"J Virol"},{"key":"3948_CR85","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.18632\/aging.103001","volume":"12","author":"C Sargiacomo","year":"2020","unstructured":"Sargiacomo C, Sotgia F, Lisanti MP (2020) COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging 12:6511\u20136517. https:\/\/doi.org\/10.18632\/aging.103001","journal-title":"Aging"},{"key":"3948_CR86","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","volume":"72","author":"TU Singh","year":"2020","unstructured":"Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK (2020) Drug repurposing approach to fight COVID-19. Pharmacol Rep 72:1479\u20131508. https:\/\/doi.org\/10.1007\/s43440-020-00155-6","journal-title":"Pharmacol Rep"},{"key":"3948_CR87","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1586\/14787210.4.2.291","volume":"4","author":"E De Clercq","year":"2006","unstructured":"De Clercq E (2006) Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther 4:291\u2013302. https:\/\/doi.org\/10.1586\/14787210.4.2.291","journal-title":"Expert Rev Anti Infect Ther"},{"key":"3948_CR88","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ijid.2022.06.016","volume":"122","author":"N Stambouli","year":"2022","unstructured":"Stambouli N, Driss A, Gargouri F, Bahrini K, Arfaoui B et al (2022) COVID-19 prophylaxis with doxycycline and zinc in health care workers: a prospective, randomized, double-blind clinical trial. Int J Infect Dis 122:553\u2013558. https:\/\/doi.org\/10.1016\/j.ijid.2022.06.016","journal-title":"Int J Infect Dis"},{"key":"3948_CR89","doi-asserted-by":"publisher","first-page":"300060521101355","DOI":"10.1177\/03000605211013550","volume":"49","author":"R Mahmud","year":"2021","unstructured":"Mahmud R, Rahman MM, Alam I, Ahmed KGU, Kabir AKMH et al (2021) Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. J Int Med Res 49:3000605211013550. https:\/\/doi.org\/10.1177\/03000605211013550","journal-title":"J Int Med Res"},{"issue":"1","key":"3948_CR90","doi-asserted-by":"publisher","first-page":"e0280745","DOI":"10.1371\/journal.pone.0280745","volume":"18","author":"R Dhar","year":"2023","unstructured":"Dhar R, Kirkpatrick J, Gilbert L, Khanna A, Modi MM, Chawla RK, Dalal S, Maturu VN, Stern M, Keppler OT, Djukanovic R, Gadola SD (2023) Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: a randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU). PLoS ONE 18(1):e0280745. https:\/\/doi.org\/10.1371\/journal.pone.0280745","journal-title":"PLoS ONE"},{"key":"3948_CR91","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S2213-2600(21)00310-6","volume":"9","author":"CC Butler","year":"2021","unstructured":"Butler CC, Yu LM, Dorward J, Gbinigie O, Hayward G (2021) Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respir Med 9:1010\u20131020. https:\/\/doi.org\/10.1016\/S2213-2600(21)00310-6","journal-title":"Lancet Respir Med"},{"key":"3948_CR92","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.neuint.2009.01.022","volume":"54","author":"MK Mishra","year":"2009","unstructured":"Mishra MK, Ghosh D, Duseja R, Basu A (2009) Antioxidant potential of minocycline in Japanese encephalitis virus infection in murine neuroblastoma cells: correlation with membrane fluidity and cell death. Neurochem Int 54:464\u2013470. https:\/\/doi.org\/10.1016\/j.neuint.2009.01.022","journal-title":"Neurochem Int"},{"key":"3948_CR93","doi-asserted-by":"publisher","first-page":"e18688","DOI":"10.1371\/journal.pone.0018688","volume":"6","author":"JH Campbell","year":"2011","unstructured":"Campbell JH, Burdo TH, Autissier P, Bombardier JP, Westmoreland SV, Soulas C, Williams KC (2011) Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV NeuroAIDS. PLoS ONE 6:e18688. https:\/\/doi.org\/10.1371\/journal.pone.0018688","journal-title":"PLoS ONE"},{"key":"3948_CR94","doi-asserted-by":"publisher","DOI":"10.1086\/651277","author":"GL Szeto","year":"2010","unstructured":"Szeto GL, Brice AK, Yang HC, Barber SA, Siliciano RF, Clements JE (2010) Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+T cells. J Infect Dis. https:\/\/doi.org\/10.1086\/651277","journal-title":"J Infect Dis"},{"key":"3948_CR95","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/jac\/dkm307","volume":"60","author":"M Michaelis","year":"2007","unstructured":"Michaelis M, Kleinschmidt MC, Doerr HW, Cinatl J Jr (2007) Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. J Antimicrob Chem 60:981\u2013986. https:\/\/doi.org\/10.1093\/jac\/dkm307","journal-title":"J Antimicrob Chem"},{"key":"3948_CR96","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.bbrc.2016.07.029","volume":"478","author":"SL Leela","year":"2016","unstructured":"Leela SL, Srisawat C, Sreekanth GP, Noisakran S, Yenchitsomanus PT, Limjindaporn T (2016) Drug repurposing of minocycline against dengue virus infection. Biochem Biophys Res Commun 478:410\u2013416. https:\/\/doi.org\/10.1016\/j.bbrc.2016.07.029","journal-title":"Biochem Biophys Res Commun"},{"key":"3948_CR97","doi-asserted-by":"publisher","first-page":"e01102","DOI":"10.1128\/mbio.01102-13","volume":"5","author":"L Josset","year":"2014","unstructured":"Josset L, Zeng H, Kelly SM, Tumpey TM, Katze MG (2014) Transcriptomic characterization of the novel avian-origin Influenza A (H7N9) virus: specific host response and responses intermediate between avian (H5N1 and H7N7) and human (H3N2) viruses and implications for treatment options. MBio 5:e01102-e1113. https:\/\/doi.org\/10.1128\/mbio.01102-13","journal-title":"MBio"},{"key":"3948_CR98","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/v11080739","volume":"11","author":"SS Bawage","year":"2019","unstructured":"Bawage SS, Tiwari PM, Pillai S, Dennis VA, Singh SR (2019) Antibiotic minocycline prevents respiratory syncytial virus infection. Viruses 11:739. https:\/\/doi.org\/10.3390\/v11080739","journal-title":"Viruses"},{"key":"3948_CR99","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1021\/acs.jcim.0c00179","volume":"60","author":"J Wang","year":"2020","unstructured":"Wang J (2020) Fast identification of possible drug treatment of Coronavirus Disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model 60:3277\u20133286. https:\/\/doi.org\/10.1021\/acs.jcim.0c00179","journal-title":"J Chem Inf Model"},{"key":"3948_CR100","doi-asserted-by":"publisher","first-page":"e1800141","DOI":"10.1002\/ardp.201800141","volume":"351","author":"HAA Ezelarab","year":"2018","unstructured":"Ezelarab HAA, Abbas SH, Hassan HA, Abuo-Rahma GEDA (2018) Recentupdates of fluoroquinolones as antibacterial agents. Arch Pharm (Weinheim) 351:e1800141. https:\/\/doi.org\/10.1002\/ardp.201800141","journal-title":"Arch Pharm (Weinheim)"},{"key":"3948_CR101","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.antiviral.2011.07.012","volume":"92","author":"BN Sharma","year":"2011","unstructured":"Sharma BN, Li R, Bernhoff E, Gutteberg TJ, Rinaldo CH (2011) Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antivir Res 92:115\u2013123. https:\/\/doi.org\/10.1016\/j.antiviral.2011.07.012","journal-title":"Antivir Res"},{"key":"3948_CR102","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/j.1440-1746.1996.tb00022.x","volume":"11","author":"M Tsutsumi","year":"1996","unstructured":"Tsutsumi M, Takada A, Takase S, Sawada M (1996) Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study. J Gastroenterol Hepatol 11:1006\u20131011. https:\/\/doi.org\/10.1111\/j.1440-1746.1996.tb00022.x","journal-title":"J Gastroenterol Hepatol"},{"key":"3948_CR103","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1128\/AAC.46.10.3280-3282.2002","volume":"46","author":"H Kojima","year":"2002","unstructured":"Kojima H, Kaita KD, Hawkins K, Uhanova J, Minuk GY (2002) Use of fluoroquinolones in patients with chronic hepatitis C virus-induced liver failure. Antimicrob Agents Chemother 46:3280\u20133282. https:\/\/doi.org\/10.1128\/AAC.46.10.3280-3282.2002","journal-title":"Antimicrob Agents Chemother"},{"key":"3948_CR104","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1155\/2014\/107459","volume":"3","author":"D Arroyo","year":"2014","unstructured":"Arroyo D, Chandran S, Vagefi PA, Wojciechowski D (2014) Adjuvant ciprofloxacin for persistent BK polyomavirus infection in kidney transplant recipients. J Transpl 3:171\u2013174. https:\/\/doi.org\/10.1155\/2014\/107459","journal-title":"J Transpl"},{"key":"3948_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/135965350701200104","volume":"12","author":"SH Ali","year":"2007","unstructured":"Ali SH, Chandraker A, DeCaprio JA (2007) Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther 12:1\u20136. https:\/\/doi.org\/10.1177\/135965350701200104","journal-title":"Antivir Ther"},{"key":"3948_CR106","doi-asserted-by":"publisher","first-page":"e0130248","DOI":"10.1371\/journal.pone.0130248","volume":"10","author":"Y Enoki","year":"2015","unstructured":"Enoki Y, Ishima Y, Tanaka R, Sato K, Kimachi K (2015) Pleiotropic effects of levofloxacin, fluoroquinolone antibiotics, against influenza virus-induced lung injury. PLoS ONE 10:e0130248. https:\/\/doi.org\/10.1371\/journal.pone.0130248","journal-title":"PLoS ONE"},{"key":"3948_CR107","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.arcmed.2020.06.004","volume":"51","author":"I Karampela","year":"2020","unstructured":"Karampela I, Dalamaga M (2020) Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res 51:741\u2013742. https:\/\/doi.org\/10.1016\/j.arcmed.2020.06.004","journal-title":"Arch Med Res"},{"key":"3948_CR108","doi-asserted-by":"publisher","first-page":"304","DOI":"10.7326\/M20-2189","volume":"173","author":"JP Metlay","year":"2020","unstructured":"Metlay JP, Waterer GW (2020) Treatment of community-acquired pneumonia during the coronavirus disease 2019 (COVID-19) pandemic. Ann Intern Med 173:304\u2013305. https:\/\/doi.org\/10.7326\/M20-2189","journal-title":"Ann Intern Med"},{"key":"3948_CR109","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jinf.2020.05.046","volume":"81","author":"L Lansbury","year":"2020","unstructured":"Lansbury L, Lim B, Baskaran V, Lim WS (2020) Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect Dis 81:266\u2013275. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.046","journal-title":"J Infect Dis"},{"key":"3948_CR110","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s43440-020-00169-0","volume":"72","author":"K Marciniec","year":"2020","unstructured":"Marciniec K, Beberok A, P\u0119cak P, Boryczka S, Wrze\u015bniok D (2020) Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis. Pharmacol Rep 72:1553\u20131561. https:\/\/doi.org\/10.1007\/s43440-020-00169-0","journal-title":"Pharmacol Rep"},{"issue":"1274","key":"3948_CR111","doi-asserted-by":"publisher","first-page":"134507","DOI":"10.1016\/j.molstruc.2022.134507","volume":"15","author":"J Cardoso-Ortiz","year":"2023","unstructured":"Cardoso-Ortiz J, Leyva-Ramos S, Baines KM, G\u00f3mez-Dur\u00e1n CFA et al (2023) Novel ciprofloxacin and norfloxacin-tetrazole hybrids as potential antibacterial and antiviral agents: targeting S. aureus topoisomerase and SARS-CoV-2-MPro. J Mol Struct 15(1274):134507. https:\/\/doi.org\/10.1016\/j.molstruc.2022.134507","journal-title":"J Mol Struct"},{"key":"3948_CR112","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/s1473-3099(03)00658-3","volume":"3","author":"A Dalhoff","year":"2003","unstructured":"Dalhoff A, Shalit I (2003) Immunomodulatory effects of quinolones. Lancet Infect Dis 3:359\u2013371. https:\/\/doi.org\/10.1016\/s1473-3099(03)00658-3","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"3948_CR113","doi-asserted-by":"publisher","first-page":"e28652","DOI":"10.1002\/jmv.28652","volume":"95","author":"D Bojkova","year":"2023","unstructured":"Bojkova D, Z\u00f6ller N, Tietgen M, Steinhorst K, Bechtel M et al (2023) Repurposing of the antibiotic nitroxoline for the treatment of mpox. J Med Virol 95(3):e28652. https:\/\/doi.org\/10.1002\/jmv.28652","journal-title":"J Med Virol"},{"key":"3948_CR114","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJM199611073351907","volume":"335","author":"HS Gold","year":"1996","unstructured":"Gold HS, Moellering RC (1996) Antimicrobial-drug resistance. N Engl J Med 335:1445\u20131453. https:\/\/doi.org\/10.1056\/NEJM199611073351907","journal-title":"N Engl J Med"},{"key":"3948_CR115","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1101\/cshperspect.a027029","volume":"6","author":"KM Krause","year":"2016","unstructured":"Krause KM, Serio AW, Kane TR, Connolly LE (2016) Aminoglycosides: an overview. Cold Spring Harb Perspect Med 6:256\u2013264. https:\/\/doi.org\/10.1101\/cshperspect.a027029","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3948_CR116","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41564-018-0138-2","volume":"3","author":"S Gopinath","year":"2018","unstructured":"Gopinath S, Kim MV, Rakib T, Wong PW, van Zandt M, Barry NA, Kaisho T, Goodman AL, Iwasaki A (2018) Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner. Nat Microbiol 3:611\u2013621. https:\/\/doi.org\/10.1038\/s41564-018-0138-2","journal-title":"Nat Microbiol"},{"key":"3948_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/emboj\/19.1.1","volume":"19","author":"R Schroeder","year":"2000","unstructured":"Schroeder R, Waldsich C, Wank H (2000) Modulation of RNA function by aminoglycoside antibiotics. EMBO J 19:1\u20139. https:\/\/doi.org\/10.1093\/emboj\/19.1.1","journal-title":"EMBO J"},{"key":"3948_CR118","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.mehy.2020","volume":"52","author":"NSS Chalichem","year":"2020","unstructured":"Chalichem NSS, Bethapudi B, Mundkinajeddu D (2020) Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: plausible mechanism for repurposing strategy. Med Hypotheses 52:120\u2013126. https:\/\/doi.org\/10.1016\/j.mehy.2020","journal-title":"Med Hypotheses"},{"key":"3948_CR119","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2174\/1381612824666180403114615","volume":"24","author":"Z Khurshid","year":"2018","unstructured":"Khurshid Z, Zafar MS, Naseem M, Khan RS, Najeeb S (2018) Human oral defensins antimicrobial peptides: a future promising antimicrobial drug. Curr Pharm Des 24:1130\u20131137. https:\/\/doi.org\/10.2174\/1381612824666180403114615","journal-title":"Curr Pharm Des"},{"key":"3948_CR120","doi-asserted-by":"publisher","first-page":"317","DOI":"10.18176\/jiaci.0567","volume":"30","author":"A Izquierdo-Dominguez","year":"2020","unstructured":"Izquierdo-Dominguez A, Rojas-Lechuga MJ, Mullol J, Alobid I (2020) Olfactory dysfunction in the COVID-19 outbreak. J Invest Allergol Clin Immunol 30:317\u2013326. https:\/\/doi.org\/10.18176\/jiaci.0567","journal-title":"J Invest Allergol Clin Immunol"},{"key":"3948_CR121","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2165\/11591980-000000000-00000","volume":"28","author":"U Thiem","year":"2011","unstructured":"Thiem U, Heppner HJ, Pientka L (2011) Elderly patients with community-acquired pneumonia: optimal treatment strategies. Drugs Aging 28:519\u2013537. https:\/\/doi.org\/10.2165\/11591980-000000000-00000","journal-title":"Drugs Aging"},{"key":"3948_CR122","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4103\/meajo.MEAJO_255_16","volume":"24","author":"KA Al-Abduljabbar","year":"2017","unstructured":"Al-Abduljabbar KA, Stone DU (2017) Risks of cefuroxime prophylaxis for postcataract endophthalmitis. Middle East Afr J Ophthalmol 24:24\u201329. https:\/\/doi.org\/10.4103\/meajo.MEAJO_255_16","journal-title":"Middle East Afr J Ophthalmol"},{"key":"3948_CR123","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1080\/07391102.2020.1777904","volume":"39","author":"AB Durojaiye","year":"2021","unstructured":"Durojaiye AB, Clarke JRD, Stamatiades GA, Wang C (2021) Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies. J Biomol Struct Dyn 39:4547\u20134554. https:\/\/doi.org\/10.1080\/07391102.2020.1777904","journal-title":"J Biomol Struct Dyn"},{"key":"3948_CR124","doi-asserted-by":"publisher","first-page":"104320","DOI":"10.1016\/j.bioorg.2020.104320","volume":"104","author":"MK Mandal","year":"2020","unstructured":"Mandal MK, Ghosh S, Bhat HR, Naesens L, Singh UP (2020) Synthesis and biological evaluation of substituted phenyl azetidine-2-one sulphonyl derivatives as potential antimicrobial and antiviral agents. Bioorg Chem 104:104320. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104320","journal-title":"Bioorg Chem"},{"key":"3948_CR125","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","volume":"26","author":"B Mercorelli","year":"2018","unstructured":"Mercorelli B, Pal\u00f9 G, Loregian A (2018) Drug repurposing for viral infectious diseases: how far are we? Trends Microbiol 26:865\u2013876. https:\/\/doi.org\/10.1016\/j.tim.2018.04.004","journal-title":"Trends Microbiol"},{"key":"3948_CR126","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.antiviral.2015.12.012","volume":"126","author":"FS Varghese","year":"2016","unstructured":"Varghese FS, Kaukinen P, Gl\u00e4sker S, Bespalov M, Hanski L, Wennerberg K, K\u00fcmmerer BM, Ahola T (2016) Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antivir Res 126:117\u2013124. https:\/\/doi.org\/10.1016\/j.antiviral.2015.12.012","journal-title":"Antivir Res"},{"key":"3948_CR127","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/jphp.13273","volume":"72","author":"JP Jourdan","year":"2020","unstructured":"Jourdan JP, Bureau R, Rochais C, Dallemagne P (2020) Drug repositioning: a brief overview. J Pharm Pharmacol 72:1145\u20131151. https:\/\/doi.org\/10.1111\/jphp.13273","journal-title":"J Pharm Pharmacol"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-024-03948-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-024-03948-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-024-03948-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T22:05:28Z","timestamp":1732053928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-024-03948-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":127,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3948"],"URL":"https:\/\/doi.org\/10.1007\/s00284-024-03948-7","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"427"}}